Cytotoxic tumor necrosis factor activity produced by equine alveolar macrophages: preliminary characterization.

[1]  R. MacKay,et al.  Tumor necrosis factor activity in the circulation of horses given endotoxin. , 1991, American journal of veterinary research.

[2]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[3]  S. Uccini,et al.  Immunoreactivity for IL-1 beta and TNF alpha in human lymphoid and nonlymphoid tissues. , 1989, The American journal of pathology.

[4]  W. Buurman,et al.  Inhibitory effect of corticosteroids on the secretion of tumour necrosis factor (TNF) by monocytes is dependent on the stimulus inducing TNF synthesis. , 1989, Clinical and experimental immunology.

[5]  R. Strieter,et al.  Dynamics of dibutyryl cyclic AMP- and prostaglandin E2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression , 1989, Infection and immunity.

[6]  S. Zuckerman,et al.  Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. , 1989, Journal of immunology.

[7]  J. Haas,et al.  Downregulation of Tumor Necrosis Factor Expression in the Human Mono‐Mac‐6 Cell Line by Lipopolysaccharide , 1989, Journal of leukocyte biology.

[8]  R. Devlin,et al.  Journal of Leukocyte Biology 45:353-361 (1989) Differential Production of Tumor Necrosis Factor, Macrophage Colony Stimulating Factor, and Interleukin 1 by Human Alveolar Macrophages , 2022 .

[9]  C. Maury,et al.  Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. , 1989, Arthritis and rheumatism.

[10]  H. Friedman,et al.  Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. , 1988, Journal of immunology.

[11]  B. Bonavida,et al.  Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. , 1988, Journal of immunology.

[12]  L. Davis,et al.  Comparative effects of tumor necrosis factor-alpha and IL-1 beta on mitogen-induced T cell activation. , 1988, Journal of immunology.

[13]  D. Gemsa,et al.  Potentiation of lymphokine-induced macrophage activation by tumor necrosis factor-alpha. , 1988, Journal of immunology.

[14]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[15]  V. Garsky,et al.  Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Tavernier,et al.  EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER , 1987, The Lancet.

[17]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[18]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[19]  T. Decker,et al.  Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. , 1987, Journal of immunology.

[20]  J. Larrick,et al.  Tumor necrosis factor production by human sarcoid alveolar macrophages. , 1986, The American journal of pathology.

[21]  D. R. Wilson,et al.  Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro , 1986, The Journal of cell biology.

[22]  J. Gamble,et al.  Stimulation of neutrophils by tumor necrosis factor. , 1986, Journal of immunology.

[23]  B. Beutler,et al.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. , 1986, Science.

[24]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[25]  J. Vilček,et al.  Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors , 1986, The Journal of experimental medicine.

[26]  B. Beutler,et al.  Brief Definitive Report Cachectin/tumor Necrosis Factor Stimulates Collagenase and Prostaglandin E2 Production by Human Synovial Cells and Dermal , 2022 .

[27]  H. Koren,et al.  Lipopolysaccharide (LPS) stimulates fresh human monocytes to lyse actinomycin D-treated WEHI-164 target cells via increased secretion of a monokine similar to tumor necrosis factor. , 1985, Journal of immunology.

[28]  B. Aggarwal,et al.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. , 1985, Science.

[29]  J. Tavernier,et al.  Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition. , 1985, The Journal of biological chemistry.

[30]  J. Elias,et al.  Differential interleukin 1 elaboration by unfractionated and density fractionated human alveolar macrophages and blood monocytes: relationship to cell maturity. , 1985, Journal of immunology.

[31]  J. Tavernier,et al.  Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. , 1985, European journal of biochemistry.

[32]  A. Sakurai,et al.  PURIFICATION AND PARTIAL AMINO ACID SEQUENCE OF RABBIT TUMOR NECROSIS FACTOR , 1985, International journal of cancer.

[33]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[34]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.

[35]  B. Beutler,et al.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells , 1985, The Journal of experimental medicine.

[36]  D. Goeddel,et al.  Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.

[37]  R. Crystal,et al.  Normal human alveolar macrophages obtained by bronchoalveolar lavage have a limited capacity to release interleukin-1. , 1984, The Journal of clinical investigation.

[38]  L. Old,et al.  Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Männel,et al.  Macrophages as a source of tumoricidal activity (tumor-necrotizing factor) , 1980, Infection and immunity.

[40]  A. Mantovani,et al.  Cytotoxicity on tumour cells of human mononuclear phagocytes: defective tumoricidal capacity of alveolar macrophages. , 1980, Clinical and experimental immunology.

[41]  N. Matthews,et al.  Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. , 1978, British Journal of Cancer.

[42]  L. Old,et al.  Partial purification of a serum factor that causes necrosis of tumors. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Lloyd J. Old,et al.  Effect of tumour necrosis factor on cultured human melanoma cells , 1975, Nature.

[44]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Forrest,et al.  Letter: Procaine and malignant hyperthermia. , 1974, Lancet.

[46]  S. Mittnacht,et al.  Antiviral effects of recombinant tumour necrosis factor in vitro , 1986, Nature.